Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.
Last trade$1.94
Day change-$0.08 (-3.96%)
Day range$1.90 – $2.03
Volume10,620
Market cap$2M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.99M
Price / earnings
—
Price / book
0.37×
Price / sales
0.24×
EV / sales
2.27×
EV / EBITDA
-0.81×
Profitability
Earnings per share
-$33.90
Return on assets
-92.05%
Return on equity
-626.45%
Dividend yield
0%
Liquidity and leverage
Debt / equity
4.14×
Current ratio
4.1×
Quick ratio
3.92×
Cash ratio
0.83×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$21.22M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for XAIR, quarterly periods
Line item
Q2 FY2027 Sep 30, 2026
Q1 FY2027 Jun 30, 2026
Q4 FY2026 Mar 31, 2026
Q3 FY2026 Dec 31, 2025
Q2 FY2026 Sep 30, 2025
Q1 FY2026 Jun 30, 2025
Q4 FY2025 Mar 31, 2025
Q3 FY2025 Dec 31, 2024
Revenue
$2.32M
$1.77M
$1.91M
$2.19M
$1.82M
$1.76M
$1.15M
$1.07M
Cost of revenue
$2.13M
$1.54M
$1.81M
$1.89M
$2.12M
$1.6M
$1.18M
$1.29M
Gross profit
$197K
$225K
$94K
$300K
-$298K
$156K
-$32K
-$215K
Selling, general and administrative
$4.59M
$4.88M
$4.99M
$4.47M
$4.91M
$4.69M
$3.88M
$7.73M
Research and development
$1.58M
$1.96M
$2.28M
$2.43M
$2.45M
$3.09M
$3.26M
$3.01M
Total operating expenses
$6.17M
$6.84M
$7.26M
$6.9M
$7.36M
$7.77M
$7.14M
$10.74M
Operating income
-$5.98M
-$6.61M
-$7.17M
-$6.6M
-$7.66M
-$7.62M
-$7.17M
-$10.95M
Interest expense
-$1.5M
-$1.49M
-$1.24M
-$1.09M
-$639K
-$548K
-$580K
-$549K
Income before taxes
-$8.18M
-$8.15M
-$10.37M
-$7.63M
-$8.26M
-$8.08M
-$8.06M
-$13.33M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$8.18M
-$8.15M
-$10.37M
-$7.63M
-$8.26M
-$8.08M
-$8.06M
-$13.33M
Net income attributable to common shareholders
-$7.82M
-$7.94M
-$10.28M
-$7.34M
-$7.94M
-$7.69M
-$8.03M
-$13.03M
EBITDA
-$5.13M
-$5.82M
-$6.34M
-$5.8M
-$6.84M
-$6.81M
-$6.33M
-$10.16M
Basic earnings per share
-$3.76
-$11.00
-$15.56
-$17.00
-$24.98
-$30.67
-$35.81
-$59.20
Diluted earnings per share
-$3.76
-$11.00
-$15.56
-$17.00
-$24.98
-$30.67
-$35.81
-$59.20
Recent news
Company coverage with links to the original publishers.
Beyond Air has agreed to sell its 58% stake in NeuroNOS to UNIVO Pharmaceutical Industries in exchange for 19.99% equity stake in UNIVO and up to $32.5 million in development and commercial milestone payments. The transaction allows Beyond Air to focus on its core LungFit business while NeuroNOS gains dedicated resources to advance its neurological disorder and brain cancer treatment pipeline.
Beyond Air reported fiscal 2026 revenue of $7.7 million, up 107% year-over-year, with a 90% customer renewal rate. The company is focusing resources on its LungFit PH nitric oxide delivery system and expects FDA approval of its second-generation device in late 2026. Management projects 2027 revenue of $16-18 million (110%+ growth) assuming Gen 2 launch, with expanded market access through three major GPO agreements covering ~7,000 hospitals. The company reduced net cash burn by 56% and achieved gross profit of $300,000 in fiscal 2026.
Beyond Air (XAIR) is urging stockholders to vote in favor of a reverse stock split (1-for-2 to 1-for-20 ratio) at a June 18, 2026 special meeting to maintain its Nasdaq listing. The company received a delisting notice from Nasdaq on April 7, 2026, due to its stock price falling below the $1.00 minimum bid requirement for 30 consecutive business days. The reverse split is necessary to increase the per-share price and avoid delisting, which would impact capital access and investor eligibility.
Beyond Cancer, Ltd. presented updated Phase 1 trial data showing six of ten heavily pre-treated cancer patients remain alive 22-40 months after a single UNO (ultra-high concentration nitric oxide) injection. Two triple negative breast cancer patients showed no evidence of disease. The company also received a U.S. patent allowance for its proprietary gas delivery technology. Safety profile was generally favorable with mostly Grade 1-2 adverse events.
Beyond Air, Inc. (NASDAQ: XAIR) announced that Chairman & CEO Steve Lisi will participate in the 38th Annual Roth Conference on March 23, 2026, in Laguna Niguel, CA. The company will present via fireside chat and offer one-on-one meetings with investors. Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on nitric oxide therapies for respiratory illnesses, neurological disorders, and solid tumors.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.